Tafluprost is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is available as eye drops for ophthalmic use. MedsAcross supplies Tafluprost for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ZIOPTAN® is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ZIOPTAN is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Source: US FDA prescribing information
Tafluprost acid, a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.
Source: US FDA prescribing information
Apply one drop in the affected eye(s) once daily in the evening. Recommended Dosage The recommended dosage is one drop in the conjunctival sac of the affected eye(s) once daily in the evening.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
. Most common ocular adverse reaction is conjunctival hyperemia (4% to 20%).
Source: US FDA prescribing information
Store refrigerated at 2° to 8°C (36° to 46°F). During shipment ZIOPTAN may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 2 days. After the pouch is opened, unopened single-dose containers may be stored in the opened foil pouch for up to 30 days at room temperature 20° to 25°C (68° to 77°F). Store in the original pouch. Protect from moisture.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Tafluprost, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Tafluprost 0.0045 mg/0.3 mL eye dropsOphthalmic Cold chainGeneric name | — | US FDA | Available on request |
| Zioptan 0.015 mg/mL eye dropsOphthalmic Cold chain | Thea Pharma | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 10 February 2012 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Tafluprost in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Tafluprost and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Tafluprost, including Zioptan.
Yes. The US FDA first approved Tafluprost on 10 February 2012, according to Drugs@FDA.
At least one listed presentation of Tafluprost must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tafluprost is classified under ATC code S01EE05 (Tafluprost).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.